Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology
Shenghao Zhang,Jiahui Ma,Yilei Ma,Jia Yi,Beier Wang,Hanbing Wang,Qinsi Yang,Kun Zhang,Xiaoqing Yan,Da Sun,Jinfeng You
DOI: https://doi.org/10.2147/ijn.s492651
IF: 7.033
2024-10-28
International Journal of Nanomedicine
Abstract:Shenghao Zhang, 1, &ast Jiahui Ma, 1, &ast Yilei Ma, 1, &ast Jia Yi, 1 Beier Wang, 2 Hanbing Wang, 3 Qinsi Yang, 4 Kun Zhang, 5 Xiaoqing Yan, 6 Da Sun, 1, 7 Jinfeng You 8 1 Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, 325035, People's Republic of China; 2 Department of Hepatobiliary-Pancreatic Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China; 3 Department of Biotechnology, The University of Hong Kong, Hong Kong SAR, 999077, People's Republic of China; 4 Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325000, People's Republic of China; 5 Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, 404000, People's Republic of China; 6 The Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, People's Republic of China; 7 Department of Endocrinology, Yiwu Central Hospital, The Affiliated Yiwu hospital of Wenzhou Medical University, Yiwu, 322000, People's Republic of China; 8 Department of Obstetrics, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jinfeng You; Da Sun, Email ; Background: Diabetes Mellitus (DM) is a substantial health concern worldwide, and its incidence is progressively escalating. Conventional pharmacological interventions frequently entail undesirable side effects, and while probiotics offer benefits, they are hindered by constraints such as diminished stability and effectiveness within the gastrointestinal milieu. Given these complications, the advent of bioengineered probiotics is a promising alternative for DM management. Aim of Review: The objective of this review is to provide an exhaustive synthesis of the most recent studies on the use of engineered probiotics in the management of DM. This study aimed to clarify the mechanisms through which these probiotics function, evaluate their clinical effectiveness, and enhance public awareness of their prospective advantages in the treatment of DM. Key Scientific Concepts of Review: Scholarly critiques have explored diverse methodologies of probiotic engineering, including physical alteration, bioenrichment, and genetic manipulation. These techniques augment the therapeutic potency of probiotics by ameliorating gut microbiota, fortifying the intestinal barrier, modulating metabolic pathways, and regulating immune responses. Such advancements have established engineered probiotics as a credible therapeutic strategy for DM, potentially providing enhanced results compared to conventional treatments. Keywords: engineered probiotics, diabetes mellitus, gut microbiota, genetic engineering, therapeutic efficacy Graphical Diabetes mellitus (DM) is a chronic disease characterized by elevated blood glucose levels owing to inadequate insulin secretion or ineffective insulin action. 1 Globally, DM is a major public health concern, with significant impacts on individuals, health systems, and national economies owing to its high prevalence and numerous complications. 2,3 According to the International Diabetes Federation, as of 2021, 537 million adults are affected by DM, with three-quarters residing in low - and middle-income countries, leading to an estimated health expenditure of at least US$ 966. 4 This burden is projected to increase, with 783.2 million people expected to be affected by 2045. 5 There are two primary types of DM: type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). 1 T1DM, which mainly affects children and adolescents, is caused by autoimmune destruction of islet β cells, leading to insufficient insulin secretion. 6 Daily insulin injections are the standard treatment. In contrast, T2DM, which can occur at any age, is becoming increasingly prevalent in children and adolescents. 7 It is characterized by insulin resistance (IR) and varying degrees of insulin deficiency. T2DM management involves lifestyle interventions and sometimes medications. 8 However, the increasing number of DM cases underscores the inadequacies of the current treatments, which often have side effects. For instance, oral insulin is degraded by the gastr -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology